Ambroxol | 氨溴索碱 | NA-872 | Bromhexine Metabolite

首页 / 抑制剂/激动剂 / / / Ambroxol

氨溴索 /Ambroxol {[allProObj[0].p_purity_real_show]}

货号：A233160 同义名： 氨溴索碱 / NA-872

Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus.

Ambroxol 化学结构
CAS号：18683-91-5

Ambroxol 3D分子结构
CAS号：18683-91-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Ambroxol 纯度/质量文件产品仅供科研

货号：A233160 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

自噬亚型比较

产品名称	Autophagy ↓ ↑	其他靶点	纯度
SBI-0206965	+++ ULK1, IC50: 108 nM ULK2, IC50: 711 nM		97%
Hydroxychloroquine sulfate	✔		99%
Valproic acid sodium	✔	HDAC	97%
PFK-015	++ PFKFB3, IC50: 207 nM		99%+
MRT68921 hydrochloride	++++ ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM		99%+
ROC-325	✔		99%+
Autophinib	+++ Autophagy, IC50: 40 nM		97%
Lys05	✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ambroxol 生物活性

靶点	Sodium Channel Sodium channel, IC50:35.2 μM-22.5 μM
描述	Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus.

Ambroxol 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02373891	Healthy Volunteers	Phase 1	Completed	-	-
NCT03177889	Bronchiectasis Adult ... 展开 >> Traditional Chinese Medicine Quality of Life Exacerbation 收起 <<	Not Applicable	Not yet recruiting	December 31, 2019	-
NCT02395913	Healthy Male	Phase 1	Completed	-	-

Ambroxol 参考文献

[1]Mao Z, Wang X, et al. Quantitative Detection of Ambroxol in Human Plasma Using HPLC-APCI-MS/MS: Application to a Pharmacokinetic Study. Anal Sci. 2017;33(10):1099-1103.

[2]Migdalska-Richards A, Ko WKD, et al. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. 2017 Jul;71(7).

Ambroxol 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.22mL

2.64mL

1.32mL

26.45mL

5.29mL

2.64mL

Ambroxol 技术信息

CAS号	18683-91-5
分子式	C₁₃H₁₈Br₂N₂O
分子量	378.1

别名	氨溴索碱 ;NA-872
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,2-8°C

溶解度

DMSO: 190 mg/mL(502.51 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02373891	Healthy Volunteers	Phase 1	Completed	-	-
NCT03177889	Bronchiectasis Adult ... 展开 >> Traditional Chinese Medicine Quality of Life Exacerbation 收起 <<	Not Applicable	Not yet recruiting	December 31, 2019	-
NCT02395913	Healthy Male	Phase 1	Completed	-	-
NCT02036775	Healthy	Phase 1	Completed	-	Russian Federation ... 展开 >> 18.510.2 Boehringer Ingelheim Investigational Site St. Petersburg, Russian Federation 收起 <<
NCT00148499	Pharyngitis	Phase 3	Completed	-	Romania ... 展开 >> Medicover Bucharest, Romania, 010224 Medicover Bucharest, Romania, 010626 Medicover Bucharest, Romania, 021106 Victor Babes Clincial Hospital Bucharest, Romania, 030303 Ukraine Regional Student Hospital Kharkov, Ukraine, 61002 Regional Clinical Hospital Kharkov, Ukraine, 61022 City Clinical Otolaryngological Hospital Kharkov, Ukraine, 61024 City Clinical Hospital No. 17 Kharkov, Ukraine, 61037 City Clinical Hospital No. 11 Kharkov, Ukraine, 61050 City Clinical Hospital No. 26 Kharkov, Ukraine, 61072 Academy of Medical Science named after O.S. Kolomyichenko Kiev, Ukraine, 03057 City Clinical Hospital No. 9 Kiev, Ukraine, 04112 City Clinical Hospital No. 11 Odessa, Ukraine, 65006 Regional Clinical Hospital Zaporozhye, Ukraine, 69600 收起 <<
NCT00525044	Pharyngitis	Phase 3	Completed	-	China ... 展开 >> Boehringer Ingelheim Investigational Site Nanjing, China Boehringer Ingelheim Investigational Site Shanghai, China ENT Subsidiary of Fudan University Hospital Shanghai, China Boehringer Ingelheim Investigational Site Wuhan, China 收起 <<
NCT01713179	In the Present Study, we Inves... 展开 >>tigated the Effects of Oral Ambroxol on Tear Film and Ocular Surface. 收起 <<	Phase 1 Phase 2	Completed	-	Korea, Republic of ... 展开 >> Hallym University, Kangnam Sacred Heart Hospital Seoul, Korea, Republic of, 150-950 收起 <<
NCT00144274	Pharyngitis	Phase 3	Completed	-	South Africa ... 展开 >> Boehringer Ingelheim Investigational Site Boksburg, South Africa, 1461 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7646 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7700 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7945 Boehringer Ingelheim Investigational Site Durban, South Africa, 4091 Boehringer Ingelheim Investigational Site Johannesburg, South Africa, 2033 Boehringer Ingelheim Investigational Site Johannesburg, South Africa, 2192 Boehringer Ingelheim Investigational Site Krugersdorp, South Africa, 1739 Boehringer Ingelheim Investigational Site Midrand, South Africa, 1685 Boehringer Ingelheim Investigational Site Pretoria, South Africa, 0038 Boehringer Ingelheim Investigational Site Pretoria, South Africa, 0157 Boehringer Ingelheim Investigational Site Sandton, South Africa, 2021 收起 <<
NCT02036775	-		Completed	-	-
NCT02194257	Healthy	Phase 1	Completed	-	-
NCT02572609	Healthy	Phase 1	Completed	-	-
NCT02194283	Healthy	Phase 1	Completed	-	-
NCT02194270	Healthy	Phase 1	Completed	-	-
NCT02572609	-		Completed	-	-
NCT03583658	Pharyngitis	Phase 3	Completed	-	South Africa ... 展开 >> Investigational Site Number 7100005 Johannesburg, South Africa 收起 <<
NCT01361802	Pharyngitis P... 展开 >>ain 收起 <<	Phase 2	Completed	-	South Africa ... 展开 >> 18.504.27015 Boehringer Ingelheim Investigational Site Bloemfontein, South Africa 18.504.27005 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27011 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27013 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27014 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27008 Boehringer Ingelheim Investigational Site Durban, South Africa 18.504.27010 Boehringer Ingelheim Investigational Site Durban, South Africa 18.504.27001 Boehringer Ingelheim Investigational Site Johannesburg, South Africa 18.504.27004 Boehringer Ingelheim Investigational Site Klipspruit West, South Africa 18.504.27003 Boehringer Ingelheim Investigational Site Krugersdorp, South Africa 18.504.27002 Boehringer Ingelheim Investigational Site Lenasia, South Africa 18.504.27006 Boehringer Ingelheim Investigational Site Newtown, South Africa 18.504.27012 Boehringer Ingelheim Investigational Site Paarl, South Africa 18.504.27007 Boehringer Ingelheim Investigational Site Pretoria, South Africa 18.504.27009 Boehringer Ingelheim Investigational Site Sydenham, South Africa 收起 <<
NCT01573663	Healthy	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Samsung medical center Seoul, Korea, Republic of 收起 <<
NCT02914366	Parkinson's Disease Dementia	Phase 2	Recruiting	December 2018	Canada, Ontario ... 展开 >> Parkwood Institute Recruiting London, Ontario, Canada, N6C 0A7 Contact: Carolina Silveira, Ph.D 519-646-6100 ext 42367 Carolina.Silveira@sjhc.london.on.ca Contact: Tommy Li, MSc 519-646-6100 ext 42711 Zhonghan.Li@sjhc.london.on.ca 收起 <<
NCT02194296	Healthy	Phase 1	Completed	-	-
NCT02941822	Parkinson Disease	Phase 2	Active, not recruiting	April 2018	United Kingdom ... 展开 >> Leonard Wolfson Experimental Neurology Centre Clinical Research Facility LWENC CRF London, United Kingdom 收起 <<
NCT03415269	Cough	Phase 2	Not yet recruiting	May 2018	United Kingdom ... 展开 >> Castle Hill Hospital Cottingham, East Yorkshire, United Kingdom, HU16 5JQ 收起 <<
NCT01463215	Type I Gaucher Disease	Phase 1 Phase 2	Suspended	August 2015	United States, New Jersey ... 展开 >> ExSAR Corporation Monmouth Junction, New Jersey, United States, 08852 收起 <<

氨溴索 /Ambroxol {[allProObj[0].p_purity_real_show]}

Ambroxol 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Ambroxol 质控信息

Ambroxol 生物活性

Ambroxol 临床研究

Ambroxol 参考文献

Ambroxol 实验方案

Ambroxol 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

氨溴索 /Ambroxol {[allProObj[0].p_purity_real_show]}

Ambroxol 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Ambroxol 质控信息

Ambroxol 生物活性

Ambroxol 临床研究

Ambroxol 参考文献

Ambroxol 实验方案

Ambroxol 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Ambroxol 纯度/质量文件产品仅供科研